HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT05145413

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Phoenix and 165 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study clarity

Study information

Study start dateStarted: November 12, 2021
Recruitment status
Completed
Enrollment listed in the registry
396
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, United Kingdom, Bulgaria, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT05145413
Official title
Show the full official title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Phoenix, United States · Little Rock, United States · Anaheim, United States

127 more locations
  • Bellflower, United States
  • Cerritos, United States
  • Costa Mesa, United States
  • Culver City, United States
  • Garden Grove, United States
  • La Habra, United States
  • Lafayette, United States
  • Lemon Grove, United States
  • Los Angeles, United States
  • Oceanside, United States
  • Orange, United States
  • Pico Rivera, United States
  • Riverside, United States
  • San Diego, United States
  • Stanford, United States
  • Torrance, United States
  • Coral Gables, United States
  • Hialeah, United States
  • Lauderhill, United States
  • Miami, United States
  • Miami Lakes, United States
  • Miami Springs, United States
  • Orange City, United States
  • Pembroke Pines, United States
  • Tampa, United States
  • Atlanta, United States
  • Augusta, United States
  • Decatur, United States
  • Marietta, United States
  • Savannah, United States
  • Chicago, United States
  • Prairie Village, United States
  • Monroe, United States
  • Gaithersburg, United States
  • Boston, United States
  • Worcester, United States
  • Ann Arbor, United States
  • Grand Rapids, United States
  • Kalamazoo, United States
  • St Louis, United States
  • Omaha, United States
  • Las Vegas, United States
  • Berlin, United States
  • New York, United States
  • Rochester, United States
  • Staten Island, United States
  • Hickory, United States
  • Cincinnati, United States
  • Garfield Heights, United States
  • Independence, United States
  • Oklahoma City, United States
  • Eugene, United States
  • Austin, United States
  • DeSoto, United States
  • Fort Worth, United States
  • Houston, United States
  • Irving, United States
  • Richardson, United States
  • Richmond, United States
  • Rutland, United States
  • Bellevue, United States
  • Kazanlak, Bulgaria
  • Cherven Bryag, Bulgaria
  • Dupnitsa, Bulgaria
  • Kardzhali, Bulgaria
  • Novi Iskar, Bulgaria
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Razgrad, Bulgaria
  • Sliven, Bulgaria
  • Sofia, Bulgaria
  • Targovishte, Bulgaria
  • Varna, Bulgaria
  • Vratsa, Bulgaria
  • Guwahati, India
  • Ahmedabad, India
  • Surat, India
  • Vadodara, India
  • Belgavi, India
  • Mangalore, India
  • Mysore, India
  • Kozhikode, India
  • Aurangabad, India
  • Mumbai, India
  • Nagpur, India
  • Nashik, India
  • Ajmer, India
  • Bikaner, India
  • Rajkot, India
  • Lucknow, India
  • Kōnan, Japan
  • Toyoake-shi, Japan
  • Shirakawa, Japan
  • Karatsu-shi, Japan
  • Fukuoka, Japan
  • Tokyo, Japan
  • Bialystok, Poland
  • Gdansk, Poland
  • Grudziądz, Poland
  • Kielce, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Siemianowice Śląskie, Poland
  • Suchy Las, Poland
  • Tuszyn, Poland
  • Brasov, Romania
  • Bucharest, Romania
  • Craiova, Romania
  • Galati, Romania
  • Iași, Romania
  • Sibiu, Romania
  • Belgrade, Serbia
  • Kovin, Serbia
  • Kragujevac, Serbia
  • Niš, Serbia
  • Novi Kneževac, Serbia
  • Vršac, Serbia
  • Pool, Reruth, United Kingdom
  • Brighton, United Kingdom
  • London, United Kingdom
  • Ashton-under-Lyne, United Kingdom
  • Manchester, United Kingdom
  • Maidstone, United Kingdom
  • Oxford, United Kingdom
  • Glasgow, United Kingdom
  • Chertsey, United Kingdom
  • Birmingham, United Kingdom
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Karuna Therapeutics, Inc., a Bristol Myers Squibb company.

Did this study involve medication?

Yes. The study involved medication, including Xanomeline and Trospium Chloride Capsules and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies